Dendrogenix Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$15.8M
- Investors
-
2
Dendrogenix General Information
Description
Operator of a biotech company intended to develop molecules, dendrogenins, to address good unmet medical needs in hearing loss and neurology. The company's molecules address the important medical needs in the field of neurodegenerative diseases, enabling medical practitioners to have a treatment alternative for hearing loss and cancer.
Contact Information
Website
www.dendrogenix.comCorporate Office
- Avenue de l Hopital, 11
- SPS Batiment 34, 3rd Floor
- 4000 Liege
- Belgium
Corporate Office
- Avenue de l Hopital, 11
- SPS Batiment 34, 3rd Floor
- 4000 Liege
- Belgium
Dendrogenix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 20-Dec-2023 | $15.8M | Completed | Clinical Trials - Phase 1 | ||
| 4. Accelerator/Incubator | 03-Jun-2019 | Completed | Product Development | |||
| 3. Early Stage VC | 18-Dec-2018 | Completed | Product Development | |||
| 2. Grant | 10-Nov-2018 | $2.8M | $1.94M | Completed | Product Development | |
| 1. Early Stage VC | 10-Nov-2018 | $1.94M | $1.94M | Completed | Product Development |
Dendrogenix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class B | ||||||||
| Class A | ||||||||
| Class B | ||||||||
| Class A | ||||||||
| Ordinary | 1,028,824 | $4.23 | $4.23 | 1x | $4.23 | 7.94% | ||
| Ordinary | 144,679 | $3.38 | $3.38 | 1x | $3.38 | 2.23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Dendrogenix Patents
Dendrogenix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023291645-A1 | Compounds derived from sterols for the treatment of a disease associated with a mitochondrial deficit | Pending | 14-Jun-2022 | ||
| EP-4539852-A1 | Compounds derived from sterols for the treatment of a disease associated with a mitochondrial deficit | Active | 14-Jun-2022 | ||
| US-20260183311-A1 | Compounds derived from sterols for the treatment of a disease associated with a mitochondrial deficit | Pending | 14-Jun-2022 | ||
| WO-2023242281-A1 | Compounds derived from sterols for the treatment of a disease associated with a mitochondrial deficit | Inactive | 14-Jun-2022 | ||
| EP-4539852-B1 | Sterol derivatives for treating disorders linked to a mitochondrial deficit | Active | 14-Jun-2022 | C07J41/0005 |
Dendrogenix Signals
Dendrogenix Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Noshaq | Venture Capital | Minority | ||
| Wallonie Entreprendre | Growth/Expansion | Minority |
Dendrogenix FAQs
-
When was Dendrogenix founded?
Dendrogenix was founded in 2018.
-
Where is Dendrogenix headquartered?
Dendrogenix is headquartered in Liege, Belgium.
-
What is the size of Dendrogenix?
Dendrogenix has 12 total employees.
-
What industry is Dendrogenix in?
Dendrogenix’s primary industry is Drug Discovery.
-
Is Dendrogenix a private or public company?
Dendrogenix is a Private company.
-
What is the current valuation of Dendrogenix?
The current valuation of Dendrogenix is .
-
What is Dendrogenix’s current revenue?
The current revenue for Dendrogenix is .
-
How much funding has Dendrogenix raised over time?
Dendrogenix has raised $20.5M.
-
Who are Dendrogenix’s investors?
Noshaq and Wallonie Entreprendre have invested in Dendrogenix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process